Hims & Hers, an online health services company, saw its shares surge over 100% premarket Monday after reports indicated the Wegovy manufacturer is exploring a partnership to distribute the weight-loss drug through the platform. The news triggered a frenzy on Wall Street, with investors speculating about the potential scale of the deal and its implications for both companies. While no formal agreement has been announced, the rumor mill has already priced in significant upside, reflecting optimism about expanded access to Wegovy and Hims & Hers’ growing role in direct-to-consumer pharmaceutical distribution.